Molecular Profile | ERBB2 V842I |
Therapy | Afatinib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Create By | tyin |
Update By | tyin |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | ERBB2 V842I | colorectal cancer | sensitive | Afatinib | Preclinical | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited growth of colorectal cancer cell lines over expressing ERBB2 (HER2) V842I in culture (PMID: 26243863). | 26243863 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
(26243863) | HER2 activating mutations are targets for colorectal cancer treatment. | Full reference... |